Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); Positive on New CFO & Deal with PerkinElmer (PKI)

Canaccord Genuity reiterates a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK) price target of $12.00.

Analyst, Jeffrey Frelick, said, "GNMK announced this week that it has hired Richard B. Slansky as CFO, replacing current CFO Paul Ross, effective April 23. We view the move as a positive as it adds greater financial experience to GNMK’s management team."

"GenMark recently signed a non-exclusive license agreement with PerkinElmer (NYSE: PKI), granting GNMK access to PKI’s microfluidics patent portfolio and eliminating patent disputes with Caliper Life Sciences."

For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.

Shares of GenMark Diagnostics closed at $4.15 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Boeing (BA) PT Lowered to $240 at Stifel
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI